To include your compound in the COVID-19 Resource Center, submit it here.

Ambrilia, TaiMed deal

TaiMed received exclusive, worldwide rights from Ambrilia to develop, manufacture and commercialize protease inhibitor

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE